



1/6

SEQUENCE LISTING

RECEIVED
DEC 13 2001
TECH CENTER 1600/2300

<110> James M. Anderson
Christina M. Van Itallie

<120> Human Occludin, Its Uses and Enhancement of Drug
Absorption Using Occludin Inhibitors

<130> OCR-754.CIP

<140> US 09/891,064

<141> 2001-06-25

<150> US 09/142,732

<151> 1998-09-15

<160> 6

<170> MS DOS

<210> 1

<211> 2312

<212> DNA

<213> Homo sapiens

<220>

<221> mat_peptide

<222> complete sequence

<223> human occludin

<400> 1

```
gcctctctcc atcagacacc ccaagggttcc atccgaagca ggcggagcac 50
cgaacgcacc ccgggggtggt cagggacccc catccgtgct gccccctagg 100
agcccgcgcc tctcctctgc gccccgcctc tcgggcccga acatcgcgcg 150
gttcctttaa cagcgcgctg gcaggggtgtg ggaagcagga ccgcgtcctc 200
ccgccccctc ccatccgagt ttcaggtgaa ttggtcaccg agggaggagg 250
ccgacacacc acacctacac tcccgcgtcc acctctccct ccctgcttcc 300
tcttggcgga ggcggcagga accgagagcc aggtccagag cgccgaggag 350
ccggtctagg acgcagcaga ttggtttatc ttggaagcta aagggcattg 400
ctcatcctga agatcagctg accattgaca atcagccatg tcatccaggc 450
ctcttgaaag tccacctcct tacaggcctg atgaattcaa accgaatcat 500
tatgcaccaa gcaatgacat atatggtgga gagatgcatg ttcgaccaat 550
gctctctcag ccagcctact cttttttaccc agaagatgaa attcttact 600
tctacaaaatg gacctctcct ccaggagtga ttcggatcct gtctatgctc 650
attattgtga tgtgcattgc catctttgcc tgtgtggcct ccacgcttgc 700
ctgggacaga ggctatggaa cttccctttt aggaggtagt gtaggctacc 750
cttatggagg aagtggcttt ggtagctacg gaagtggcta tggtatggc 800
tatggttatg gctatggcta cggaggctat acagacccaa gagcagcaaa 850
gggcttcatg ttggccatgg ctgccttttg tttcattgcc gcgttggtga 900
```

```

tctttgttac cagtgttata agatctgaaa tgtccagaac aagaagatac 950
tacttaagtg tgataatagt gagtgtctatc ctgggcatca tgggtgtttat 1000
tgccacaatt gtctatataa tgggagtgaa cccaactgct cagtcttctg 1050
gatctctata tggttcacaa atatatgccc tctgcaacca attttataca 1100
cctgcagcta ctggactcta cgtggatcag tatttgtatc actactgtgt 1150
tgtggatccc caggaggcca ttgccattgt actggggttc atgattattg 1200
tggcttttgc tttaataatt ttctttgctg tgaaaactcg aagaaagatg 1250
gacaggtatg acaagtccaa tattttgtgg gacaaggaac acatttatga 1300
tgagcagccc cccaatgtcg aggagtgggt taaaaatgtg tctgcaggca 1350
cacaggacgt gccttcaccc ccatctgact atgtggaaag agttgacagt 1400
cccatggcat actcttccaa tggcaaagtg aatgacaagc ggttttatcc 1450
agagtcttcc tataaatcca cgccggttcc tgaagtgggt caggagcttc 1500
cattaacttc gcctgtggat gacttcaggc agcctcgta cagcagcgg 1550
ggtaactttg agacaccttc aaaaagagca cctgcaaagg gaagagcagg 1600
aaggtcaaag agaacagagc aagatcacta tgagacagac tacacaactg 1650
gcggcgagtc ctgtgatgag ctggaggagg actggatcag ggaatatcca 1700
cctatcactt cagatcaaca aagacaactg tacaagagga attttgacac 1750
tggcctacag gaatacaaga gcttacaatc agaacttgat gagatcaata 1800
aagaactctc ccgtttggat aaagaattgg atgactatag agaagaaagt 1850
gaagagtaca tggctgctgc tgatgaatac aatagactga agcaagtga 1900
gggatctgca gattacaaaa gtaagaagaa tcattgcaag cagttaaaga 1950
gcaaattgtc acacatcaag aagatggttg gagactatga tagacagaaa 2000
acatagaagg ctgatgccaa gttgtttgag aaattaagta tctgacatct 2050
ctgcaatctt ctcaagaaggc aaatgacttt ggaccataac cccggaagcc 2100
aaacctctgt gagcatcaca aagttttggg ttgctttaac atcatcagta 2150
ttgaagcatt ttataaatcg cttttgataa tcaactgggc tgaacaactc 2200
caattaagga ttttatgctt taaacattgg ttcttgattt aagaatgaaa 2250
tactgtttga ggtttttaag ccttaaagga aggttctggt gtgaactaaa 2300
ctttcacacc cc 2312

```

```

<210>      2
<211>      522
<212>      PRT
<213>      Homo sapiens
<220>
<221>      peptide
<222>      complete sequence
<223>      human occludin
<400>      2

```

```

Met Ser Ser Arg Pro Leu Glu Ser Pro Pro Pro Tyr Arg Pro Asp
      5                      10                      15

Glu Phe Lys Pro Asn His Tyr Ala Pro Ser Asn Asp Ile Tyr Gly
      20                      25                      30

Gly Glu Met His Val Arg Pro Met Leu Ser Gln Pro Ala Tyr Ser
      35                      40                      45

```

Phe Tyr Pro Glu Asp Glu Ile Leu His	Phe Tyr Lys Trp Thr Ser
50	55 60
Pro Pro Gly Val Ile Arg Ile Leu Ser	Met Leu Ile Ile Val Met
65	70 75
Cys Ile Ala Ile Phe Ala Cys Val Ala	Ser Thr Leu Ala Trp Asp
80	85 90
Arg Gly Tyr Gly Thr Ser Leu Leu Gly	Gly Ser Val Gly Tyr Pro
95	100 105
Tyr Gly Gly Ser Gly Phe Gly Ser Tyr	Gly Ser Gly Tyr Gly Tyr
110	115 120
Gly Tyr Gly Tyr Gly Tyr Gly Tyr Gly	Gly Tyr Thr Asp Pro Arg
125	130 135
Ala Ala Lys Gly Phe Met Leu Ala Met	Ala Ala Phe Cys Phe Ile
140	145 150
Ala Ala Leu Val Ile Phe Val Thr Ser	Val Ile Arg Ser Glu Met
155	160 165
Ser Arg Thr Arg Arg Tyr Tyr Leu Ser	Val Ile Ile Val Ser Ala
170	175 180
Ile Leu Gly Ile Met Val Phe Ile Ala	Thr Ile Val Tyr Ile Met
185	190 195
Gly Val Asn Pro Thr Ala Gln Ser Ser	Gly Ser Leu Tyr Gly Ser
200	205 210
Gln Ile Tyr Ala Leu Cys Asn Gln Phe	Tyr Thr Pro Ala Ala Thr
215	220 225
Gly Leu Tyr Val Asp Gln Tyr Leu Tyr	His Tyr Cys Val Val Asp
230	235 240
Pro Gln Glu Ala Ile Ala Ile Val Leu	Gly Phe Met Ile Ile Val
245	250 255
Ala Phe Ala Leu Ile Ile Phe Phe Ala	Val Lys Thr Arg Arg Lys
260	265 270
Met Asp Arg Tyr Asp Lys Ser Asn Ile	Leu Trp Asp Lys Glu His
275	280 285
Ile Tyr Asp Glu Gln Pro Pro Asn Val	Glu Glu Trp Val Lys Asn
290	295 300
Val Ser Ala Gly Thr Gln Asp Val Pro	Ser Pro Pro Ser Asp Tyr
305	310 315
Val Glu Arg Val Asp Ser Pro Met Ala	Tyr Ser Ser Asn Gly Lys
320	325 330

Val	Asn	Asp	Lys	Arg	Phe	Tyr	Pro	Glu	Ser	Ser	Tyr	Lys	Ser	Thr	335	340	345
Pro	Val	Pro	Glu	Val	Val	Gln	Glu	Leu	Pro	Leu	Thr	Ser	Pro	Val	350	355	360
Asp	Asp	Phe	Arg	Gln	Pro	Arg	Tyr	Ser	Ser	Gly	Gly	Asn	Phe	Glu	365	370	375
Thr	Pro	Ser	Lys	Arg	Ala	Pro	Ala	Lys	Gly	Arg	Ala	Gly	Arg	Ser	380	385	390
Lys	Arg	Thr	Glu	Gln	Asp	His	Tyr	Glu	Thr	Asp	Tyr	Thr	Thr	Gly	395	400	405
Gly	Glu	Ser	Cys	Asp	Glu	Leu	Glu	Glu	Asp	Trp	Ile	Arg	Glu	Tyr	410	415	420
Pro	Pro	Ile	Thr	Ser	Asp	Gln	Gln	Arg	Gln	Leu	Tyr	Lys	Arg	Asn	425	430	435
Phe	Asp	Thr	Gly	Leu	Gln	Glu	Tyr	Lys	Ser	Leu	Gln	Ser	Glu	Leu	440	445	450
Asp	Glu	Ile	Asn	Lys	Glu	Leu	Ser	Arg	Leu	Asp	Lys	Glu	Leu	Asp	455	460	465
Asp	Tyr	Arg	Glu	Glu	Ser	Glu	Glu	Tyr	Met	Ala	Ala	Ala	Asp	Glu	470	475	480
Tyr	Asn	Arg	Leu	Lys	Gln	Val	Lys	Gly	Ser	Ala	Asp	Tyr	Lys	Ser	485	490	495
Lys	Lys	Asn	His	Cys	Lys	Gln	Leu	Lys	Ser	Lys	Leu	Ser	His	Ile	500	505	510
Lys	Lys	Met	Val	Gly	Asp	Tyr	Asp	Arg	Gln	Lys	Thr				515	520	

<210> 3

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<221> peptide

<223> construct used in experiments

<400> 3

5/6

Cys Asp Arg Gly Tyr Gly Thr Ser Leu Leu Gly Gly Ser Val Gly
5 10 15

Tyr Pro Tyr Gly Gly Ser Gly Phe Gly
20

<210> 4

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<221> peptide

<223> construct used in experiments

<400> 4

Cys Ser Tyr Gly Ser Gly Tyr Gly Tyr Gly Tyr Gly Tyr Gly Tyr
5 10 15

Gly Tyr Gly Gly Tyr Thr Asp Pro Arg
20

<210> 5

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> peptide

<223> construct used in experiments

<400> 5

Asn His Tyr Ala Pro Ser Asn Asp Ile Tyr Gly Gly Glu Met Val
5 10 15

His Arg Pro Met Leu
20

<210> 6

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<221> peptide

<223> construct used in experiments

<400> 6

Ala Ser Gln Gln Val Tyr Arg Lys Asp Pro Cys
5 10